1. Home
  2. Research
  3. Research Groups
  4. Translational Cancer Research

Translational Cancer Research

Our group has been focused for years on the identification, characterization and validation, through multidisciplinary approaches, of prognostic/predictive markers and potential therapeutic targets in tumors, in particular breast, gynecological carcinomas and sarcomas. An additional group goal is to gain insights into the molecular basis of chemo/radioresistance in cancer and to advance in the design of new, more effective and less toxic antitumor (nano)-therapies. Among our studies, we highlight those focused on analyzing the functional role in cancer of the chromosomal instability, cell cycle, mechanisms of cell death, intratumoral heterogeneity and the immune response to tumors.

2025 Activity indicators

  • 11 competitive national public projects: AEI, ISCIII, INNOCAM
  • 5 private projects led
  • 6 competitive HR contracts
  • 6 publications · Impact Factor: 83.50
  • Publications in Q1: 3 (50%)
  • Publications in D1: 3 (50%)
  • 2 awards
  • Project evaluators for national institutions: 2 PI
  • Editorial committee members: 1 PI
    +3 months of stay at national and international centers:
    • OncoRay - Center for Radiation Research in Oncology (Dresden, Germany)
    • Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER) (Seville, Spain)
    • Prince Felipe Research Center (CIPF) (Valencia, Spain)

  • 1 visiting researcher hosted and 10.6 months of stay: National University of Mar del Plata (Argentina)

Milestones

  1. Chiara Giorgetti Award for the project: "MetaBrainTox," a project focused on the treatment of brain metastases derived from HER2-positive breast cancer with a novel nanotherapy, by Dr. Gema Moreno Bueno, awarded by the Spanish Association for Metastatic Breast Cancer (AECMM).
  2. 2025 Award for Scientific Volunteering in the field of scientific research, awarded by the Spanish Association Against Cancer (AECC) to Dr. Guillermo de Cárcer.
  3. Appointment of Dr. Gema Moreno Bueno as coordinator of the breast and gynecological cancer program at CIBERONC.
  4. Flores NG, Fernández DM, Garnés C, Domínguez A, Jiménez J, Sabater S, Fernández P, Andrés I, Cimas FJ, de Cárcer G, Belandia B, Palmero I, Huertas P, Ruiz MJ, Sánchez-Prieto R. The CDK12-BRCA1 signaling axis mediates dinaciclib-associated radiosensitivity through p53-mediated cellular senescence. Mol. Oncol. 2024;DOI:10.1002/1878-0261.13773.
  5. Monfort A, Sanz N, Ballesteros S, Ortigosa B, Cambón A, Ramos M, Lorenzo ÁM, Escribano M, Rosa JM, Martínez J, Sánchez-Prieto R, Sotillo R, de Cárcer G. Osmotic stress infl uences microtubule drug response via WNK1 kinase signaling. Drug Resist. Update. 2025;79: 101203 - 101203. DOI:10.1016/j.drup.2025.101203.

Networks and alliances